[199 Pages Report] The Cell & Gene Therapy Manufacturing Services Market size was estimated at USD 17.34 billion in 2023 and expected to reach USD 19.98 billion in 2024, at a CAGR 15.81% to reach USD 48.45 billion by 2030.
Cell and gene therapy manufacturing services encompass the specialized production processes required for the development and commercialization of cell and gene therapies. The scope of these services includes a comprehensive array of production activities such as the sourcing of raw materials, cell processing, gene transfection or vector integration, culturing, harvesting, purification, quality control, and final product formulation. As cell and gene therapies are widely considered a critical component in modern therapeutic development, the importance of robust, compliant, and scalable manufacturing capabilities becomes critical. The cell and gene therapy manufacturing services market is rapidly expanding, with the increasing prevalence of genetic disorders and cancers, advances in molecular biology, and significant investments from both the public and private healthcare sectors. Collaboration between academic institutions, biotech firms, and service providers further propels the market growth. Despite the growth, the market faces several challenges, including high costs of production, stringent and evolving regulatory requirements, and the complexity of manufacturing processes. The necessity for specialized facilities and skilled personnel increases operational challenges, and ensuring consistent quality and scalability remains a significant hurdle. However, the market is ripe with opportunities, particularly in the development of automation and closed-system manufacturing to improve efficiency and reduce contamination risks. Breakthroughs in cell and gene therapy are promising for personalized medicine, thus creating lucrative opportunities for specialized cell and gene therapy manufacturing services.
Type: Applications of autologous mesenchymal stem cells for tissue repair and anti-inflammatory treatments
Allogeneic cell therapy manufacturing encompasses the production of cells that are derived from a donor and can be used for multiple recipients. This category includes the processing of allogeneic hematopoietic stem cells for use in blood-related disorders, the generation of allogeneic Induced pluripotent stem cells (iPSCs), which are reprogrammed to an embryonic-like state and can differentiate into various cell types, the cultivation of allogeneic mesenchymal stem cells (MSCs) known for their potential in regenerative medicine and immunomodulation, as well as the expansion of allogeneic natural killer (NK) cells and allogeneic T-cells for immunotherapeutic applications. Autologous cell therapy manufacturing produces personalized treatments where the patient’s own cells are collected, processed, and then reintroduced into their body. This process is used for autologous hematopoietic stem cells, which are frequently utilized in the context of bone marrow transplants, autologous mesenchymal stem cells (MSCs) that are being explored for tissue repair and anti-inflammatory treatments, autologous natural killer (NK) cells, and autologous T-cells which can be engineered, as in CAR-T therapies, to target and destroy cancer cells. Viral vector manufacturing is a critical aspect of gene therapy, providing the means for genetic material delivery into host cells. This includes the production of adeno-associated virus (AAV) vectors preferred for their safety profile and long-term expression in non-dividing cells, and retroviral vectors, including lentiviral vectors, which are capable of integrating therapeutic genes into the host genome, thus offering the possibility of a permanent cure for some genetic diseases.
In contrast to traditional viral vectors, non-viral vector gene therapy manufacturing utilizes non-viral delivery systems such as plasmids, minicircles, or naked DNA/RNA. These methods offer certain advantages in terms of safety and reduced immunogenicity. Non-viral vectors are engineered to transport genetic materials into host cells with the aim of achieving a therapeutic effect, such as correcting a gene mutation or promoting the expression of a beneficial gene. Oligonucleotides, small strands of DNA or RNA, are crucial for a variety of gene therapy and diagnostic applications. In gene therapy, they can be used as antisense oligonucleotides to bind to specific mRNA molecules and block protein production or as small interfering RNA (siRNA) to silence target genes. The synthesis and production of oligonucleotides require high precision and stringent quality control to ensure the correct sequence and purity are achieved for therapeutic use.
Indication: Growing potential of oncology therapies for personalized medicine in patients with various malignancies
In the landscape of cell and gene therapy manufacturing services, addressing cardiovascular diseases stands as a significant domain. These therapies aim to engineer or repair cardiac tissues and modulate immune responses, offering potentially curative treatments for ailments such as myocardial infarction, cardiomyopathies, and congenital heart diseases. The field of cell and gene therapy presents promising avenues for correcting or mitigating central nervous system (CNS) disorders, which include a broad range of debilitating conditions such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. Cell and gene therapy manufacturing services are at the forefront of creating innovative solutions for infectious diseases. By utilizing genetically modified cells and viral vectors, these therapies aim to enhance the immune system’s capacity to combat pathogens and provide durable protective effects. Oncology remains a primary focus within the cell and gene therapy sector due to the high incidence and mortality rates associated with cancer. Manufacturing services are dedicated to the development of therapies such as CAR-T cells and oncolytic viruses that directly target and eliminate cancer cells while striving to minimize damage to healthy tissue. Ophthalmology diseases, including retinal degenerative disorders and corneal dystrophies, are rapidly becoming a target for cell and gene therapies. Manufacturing services in this realm concentrate on advancing precision medicine approaches that can correct genetic mutations at the source or replace dysfunctional cells within the eye. In the field of orthopedic diseases, cell and gene therapy manufacturing services are increasingly focused on the development of regenerative treatments for bone and cartilage repair. These therapies leverage the power of mesenchymal stem cells, gene editing, and growth factor delivery to promote healing and restore function. The capacity to effectively regenerate orthopedic tissues offers promising new alternatives to traditional surgical interventions, particularly for degenerative conditions like osteoarthritis.
Application: Significant benefits of customized cell & gene therapy manufacturing services for early-stage products
Clinical manufacturing pertains to the production of cell and gene therapies that are intended for clinical trials rather than widespread commercial distribution. This segment prioritizes flexibility, scalability, and speed to cater to the variable demands of clinical research. Manufacturers and service providers need to adhere to stringent regulatory requirements while maintaining cost-effectiveness to accommodate the limited volumes and highly personalized nature of these therapies. Commercial manufacturing is the large-scale production of approved cell and gene therapies for distribution in the market. This segment requires significant investment in infrastructure and process optimization to achieve the necessary economies of scale while strictly adhering to regulatory standards for quality, efficacy, and safety.
End-User: Higher preferences for cost-effective services from academic and research institutes
Academic and research institutes has a crucial role in the cell and gene therapy space as these entities are frequently at the forefront of developing new therapeutic approaches. These institutes often have specific needs based on their focus on innovation and early-stage research. They prioritize access to cutting-edge technology and platforms that allow for higher customization and flexibility, as their work often involves novel and evolving therapies. They also value services that offer scalability, given the variance in project sizes from small-scale exploratory trials to larger collaborative research ventures. Pharmaceutical and biotechnology companies generally have a more commercial focus, with a strong emphasis on the scalability, reliability, and regulatory compliance of manufacturing services. These companies seek service providers that can support the entire lifecycle of a product, from development through clinical trials to commercial-scale manufacturing. Many pharma and biotech firms opt to partner with contract development and manufacturing organizations (CDMOs) owing to the complexities and high cost of setting up in-house cell and gene therapy manufacturing facilities. These end-users demand a track record of regulatory success, robust quality systems, and an ability to handle larger batch sizes for late-stage trials and commercial production.
Regional Insights
In the Americas, the market for cell and gene therapy manufacturing services is experiencing robust growth. This upsurge is primarily driven by a well-established biotech ecosystem, substantial investments in research and development, and a favorable regulatory environment. Moreover, the presence of established market players and the high adoption rate of advanced therapies are catalyzing the market in America. The EMEA region is witnessing a significant expansion in the cell and gene therapy manufacturing service market, with Europe being at the forefront. The growth in the European Union is supported by strong governmental support, advanced healthcare infrastructure, and increasing collaborations between academic and industrial sectors. The Middle East and Africa are also showing growth potential, with increasing investment in healthcare infrastructure and a growing interest in advanced therapeutic modalities. The Asia-Pacific region is a rapidly emerging market in cell and gene therapy manufacturing services, driven by growing healthcare expenditures and a rising number of local companies entering the space. Technological advancements and increasing partnerships with Western companies are further propelling the market forward in this region.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Cell & Gene Therapy Manufacturing Services Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cell & Gene Therapy Manufacturing Services Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Cell & Gene Therapy Manufacturing Services Market, highlighting leading vendors and their innovative profiles. These include Advanced BioScience Laboratories, Inc., AGC Biologics, Bio-Techne Corporation, Bluebird Bio, Inc., Boehringer Ingelheim International GmbH, c-LEcta GmbH, Catalent, Inc., Cell and Gene Therapy Catapult, Cell Therapies Pty Ltd., Cell-Easy SAS, Charles River Laboratories International, Inc., Exmoor Pharma Concepts Limited, F. Hoffmann-La Roche Ltd., FUJIFILM Diosynth Biotechnologies, General Electric Company, Lonza Group, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Minaris Regenerative Medicine GmbH, Nikon Corporation, Novartis AG, Oxford Biomedica PLC, Recipharm AB, Resonac Corporation, Samsung Biologics Co., Ltd, Takara Holdings Inc., Thermo Fisher Scientific, Inc., uBriGene Biosciences Inc., and Wuxi Apptec Co., Ltd..
Market Segmentation & Coverage
This research report categorizes the Cell & Gene Therapy Manufacturing Services Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Type
- Cell Therapy
- Allogeneic
- Allogeneic Hematopoietic Stem Cells
- Allogeneic Induced Pluripotent Stem Cells
- Allogeneic Mesenchymal Stem Cells
- Allogeneic Natural Killer Cells
- Allogeneic T-cells
- Autologous
- Autologous Hematopoietic Stem Cells
- Autologous Mesenchymal Stem Cells
- Autologous Natural Killer Cells
- Autologous T-cells
- Viral Vector
- Adeno-associated Virus Vectors
- Retroviral Vectors
- Allogeneic
- Gene Therapy
- Non-viral Vector
- Oligonucleotides
- Cell Therapy
- Indication
- Cardiovascular Diseases
- Central Nervous System Disorders
- Infectious Diseases
- Oncology Diseases
- Ophthalmology Diseases
- Orthopedic Diseases
- Application
- Clinical Manufacturing
- Commercial Manufacturing
- End-User
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Cell & Gene Therapy Manufacturing Services Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cell & Gene Therapy Manufacturing Services Market?
- What are the technology trends and regulatory frameworks in the Cell & Gene Therapy Manufacturing Services Market?
- What is the market share of the leading vendors in the Cell & Gene Therapy Manufacturing Services Market?
- Which modes and strategic moves are suitable for entering the Cell & Gene Therapy Manufacturing Services Market?
US $
Euro €
GBP £
